Lower anti-Müllerian hormone is linked with older age in human cohorts of women. A study reports prediction of menopause during the menopausal transition, and another links lower levels with lower spine bone mineral density over 14 years. A dehydroepiandrosterone trial in women reports increased levels in diminished ovarian reserve; another shows no clear effect in primary ovarian insufficiency.
231 findings in 154 papers from 2010 to 2026, 37 of them since April 2026
“the risk of early spontaneous miscarriage was 1.57 times higher in the group with AMH < 1.1 ng/ml group (P < 0.001)”
Dehydroepiandrosterone showed no clear effect on anti-Müllerian hormone in rhesus monkeys (old macaques given short-term DHEA supplementation).
“AMH concentrations within the ovaries and circulation, assessed by Western analysis and ELISA, respectively, showed significant age-related decreases that were not attenuated by DHEA supplementation”
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·
Dehydroepiandrosterone increases anti-Müllerian hormone in O. aries.
“DHEA increased the expression of both the proliferation marker (KI-67) in granulosa cells and the follicular AMH expression at the preantral and early antral follicle stages.”
Resveratrol increases anti-Müllerian hormone in chickens (only in older hens, age-by-RES interaction).
“Plasma levels of melatonin (MT), estradiol (E2), and anti-Müllerian hormone (AMH) also showed significant interactions (P < 0.05), with RES increasing these hormones only in older hens.”
Animalsonly in older hens, age-by-RES interaction400 mg/kg12 weeks
Smoking is linked with lower anti-Müllerian hormone in humans (current smokers compared with non-smokers; former smokers also lower) (current smokers 20.3% lower (95% CI −29.2 to −10.3%); former smokers 12.7% lower (95% CI −21.2 to −3.2%)).
“Current and former smokers had 20.3% (95% CI ‒29.2 to ‒10.3%) and 12.7% (‒21.2 to ‒3.2%) lower AMH levels, respectively”
Humanscurrent smokers compared with non-smokers; former smokers also lowerfemales
Smoking is linked with lower anti-Müllerian hormone in humans (compared with never use) (12% lower, P < 0.0001).
“Current oral contraceptive (OC) use and current/former smoking were associated with lower AMH concentration than never use (40% and 12% lower, respectively, P < 0.0001).”
Oral contraceptives are linked with lower anti-Müllerian hormone in humans (current use compared with never use) (41.5% lower (95% CI −49.9 to −31.4%)).
“current oral contraceptive use was associated with 41.5% (95% CI ‒49.9 to ‒31.4%) lower AMH levels”
Oral contraceptives are linked with lower anti-Müllerian hormone in humans (compared with never use) (40% lower, P < 0.0001).
“Current oral contraceptive (OC) use and current/former smoking were associated with lower AMH concentration than never use (40% and 12% lower, respectively, P < 0.0001).”
Anti-Müllerian hormone is linked with age at menopause in humans (association of breastfeeding duration with age at menopause).
“Breastfeeding duration was positively associated with age at menopause (P for trend = 0.01), with evidence that the association was mediated via AMH.”
Humansassociation of breastfeeding duration with age at menopausefemales
Anti-Müllerian hormone was not clearly linked with multiple sclerosis status in humans (women with MS vs healthy controls) (0.98-fold difference (95% CI 0.69-1.37)).
“AMH levels were similar (0.98-fold difference, 95% confidence interval [CI] 0.69-1.37, p = 0.87) in women with MS (n = 412, mean age 42.6 years) and healthy controls (n = 180, mean age 44 years)”
Anti-Müllerian hormone was not clearly linked with probability of conception in humans (women aged 30 to 44 years trying to conceive for 3 months or less, low vs normal AMH) (65% (95% CI, 50%-75%) vs 62% (95% CI, 57%-66%) by 6 cycles).
“women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt”
Humanswomen aged 30 to 44 years trying to conceive for 3 months or less, low vs normal AMHfemales
Age is linked with lower anti-Müllerian hormone in humans (β = -0.068; 95% CI [-0.117, -0.018]).
“only age (β = -0.068; 95% CI [-0.117, -0.018]; p = 0.007) and transformed FSH (β = -3.582; 95% CI [-4.846, -2.317]; p < 0.001) remained independently associated with transformed AMH.”
Age is linked with lower anti-Müllerian hormone in humans (systemic lupus erythematosus) (OR = 1.12(1.05–1.20), p = 0.001).
“higher age [OR = 1.12(1.05–1.20), p = 0.001], active disease [OR = 3.87(1.56–9.62), p = 0.004], menstrual irregularities [OR = 4.56(1.95–10.65), p < 0.001]”
Age decreases anti-Müllerian hormone in humans (undetectable ∼5 years before menopause).
“After an initial increase until early adulthood, AMH concentrations slowly decrease with increasing age until becoming undetectable ∼5 years before menopause”
Polycystic ovary syndrome is linked with higher anti-Müllerian hormone in PCOS patients vs controls (7.54 ± 5.8 vs. 2.49 ± 2.0 ng/mL, p < 0.0001).
“Serum AMH was significantly higher among PCOS patients compared to non-PCOS controls in the non-stratified sample (7.54 ± 5.8 vs. 2.49 ± 2.0 ng/mL, respectively; p < 0.0001)”
Neutrophil-to-lymphocyte ratio was not clearly linked with anti-Müllerian hormone in humans (age-adjusted) (β = -0.012, 95% CI: -0.222 to 0.198, p = 0.912).
“After adjustment for age, neither CRP (β = -0.038, 95% CI: -0.085 to 0.009, p = 0.114) nor NLR (β = -0.012, 95% CI: -0.222 to 0.198, p = 0.912) was independently associated with AMH.”
C-reactive protein was not clearly linked with anti-Müllerian hormone in humans (age-adjusted) (β = -0.038, 95% CI: -0.085 to 0.009, p = 0.114).
“After adjustment for age, neither CRP (β = -0.038, 95% CI: -0.085 to 0.009, p = 0.114) nor NLR (β = -0.012, 95% CI: -0.222 to 0.198, p = 0.912) was independently associated with AMH.”
Polycystic ovary syndrome is associated with anti-Müllerian hormone in humans (50 women with PCOS compared with 50 controls) (6.08 ± 1.67 vs 2.49 ± 0.80 ng/mL).
“Women with PCOS had significantly higher anti-Müllerian hormone levels (6.08 ± 1.67 vs 2.49 ± 0.80 ng/mL)”
Humans50 women with PCOS compared with 50 controlsfemalesn = 100
International Journal of Clinical Obstetrics and Gynaecology·
Anti-Müllerian hormone predicts polycystic ovary syndrome in humans (AMH diagnostic cutoff of 1.17 ng/mL) (AUC 0.71 (95% CI 0.60–0.83)).
“An AMH cutoff of 1.17 ng/mL showed moderate diagnostic reliability for diagnosing PCOS in aging women, with an area under curve of 0.71 (95% CI:0.60-0.83).”
Chronological age is associated with anti-Müllerian hormone in humans (Women of reproductive age undergoing AMH testing) (Pearson's r = -0.508; Spearman's rho = -0.547; p < 0.001).
“Age showed a moderate-to-strong, significant inverse correlation with AMH (Pearson's r = -0.508, Spearman's rho = -0.547; p < 0.001)”
HumansWomen of reproductive age undergoing AMH testingserumfemalesn = 264
Chronological age is associated with anti-Müllerian hormone in humans (Chinese women attending a reproductive center clinic) (r = -0.606; average AMH decrease of 6.2% per year).
“Our results showed that serum AMH levels were negatively correlated with age (r = -0.606, p < .001).”
HumansChinese women attending a reproductive center clinicserumfemalesn = 3,280
Anti-Müllerian hormone predicts ovarian reserve in humans.
“Individual AMH serum concentration does accurately reflect the size of the pool of antral follicles, representing the quantity of the remaining primordial follicles.”
Anti-Müllerian hormone predicts clinical pregnancy in humans (infertile women undergoing IVF/ICSI) (OR 1.284, 95% CI 1.031–1.599).
“There was significant relationship between FF AMH levels and probability of clinical pregnancy in patients older than 35 years (OR=1.284, 95%CI=1.031-1.599, P=0.026).”
Anti-Müllerian hormone levels decline with age in human observational studies, and a study during the menopausal transition reports that it predicts menopause. Other human studies associate its levels with vascular age, osteoporosis, and menopausal symptoms.
Summary rewritten as its findings changed.
As it read before
In human females, anti-Müllerian hormone correlates with age, body mass index, and the COVID-19 pandemic, and predicts ovarian sensitivity to exogenous gonadotropins during IVF/ICSI cycles. Reviews also link sickle cell anemia to reduced levels.
A lactate-based protein modification supported transport channels and reduced cell death in experiments with lab-grown granulosa cells, which support developing eggs.A lactate-based protein modification supported transport channels and reduced cell death in experiments with lab-grown granulosa cells, which support developing eggs.